Oncology nurses and APPs play a key role in educating patients on BREAKWATER study findings and their impact on BRAF-mutant CRC treatment.

Key opinion leaders explore approaches to dose modifications or treatment pauses due to side effects, including examples where these adjustments significantly impacted patient outcomes.

The FDA approved tislelizumab-jsgr (Tevimbra) with platinum chemotherapy as a first-line treatment for adults with ...

Hazards of the LA wildfires necessitate awareness that first responders and those central to the fires may be at risk for ...

For patients with relapsed BRCA-mutated ovarian carcinoma, rucaparib produced a median OS of 19.4 months vs 25.4 months with ...

Avelumab in combination with axitinib was found effective and safe as frontline treatment for advanced RCC in real-world ...

Panelists discuss how emerging treatments, digital health tools, and enhanced care coordination could streamline disease ...

Panelists discuss how their lived experiences and insights as patients should inform research priorities, treatment ...

Oncology nurses are familiar with the concept of financial toxicity, which refers to the significant financial burden cancer ...

Katy Beckermann, MD, PhD, explained that oncology nurses and APPs should be ready to administer and explain dose ...

Axel Stuart Merseburger, MD, PhD, explained that with TKIs like axitinib, it is necessary for oncology nurses to spend time ...

AUTX-703, a novel, oral KAT2A/B degrader, has received fast track designation for use in relapsed/refractory AML.